Letter From The Chair and Half Year Accounts
Filed with ASX · · 26 pages · English
Although it is not our usual practice to accompany the half-year report with a Board communication, I thought it important under the circumstances to add some general comments to the accompanying financial statements. It would be an understatement to note that the last two months have been an exceptionally challenging period for Percheron and its shareholders. The negative data read-out from the a
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Topline Six-Month Results From Phase IIb Study of Avicursen
- Clinical Trial Update
- Results of Share Purchase Plan
- Percheron to launch Share Purchase Plan
- $13.0 million Institutional Placement
Later from Percheron Therapeutics
- Response to ASX Query
- Trading Halt
- Percheron licenses HMBD-002 from Hummingbird Bioscience
- Appendix 4E and Annual Report
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics